Pharvaris N.V. (PHVS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $30.02
- As of
Kresmion compiles this page from PHVS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pharvaris N.V. (PHVS): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-08.
See the full PHVS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PHVS on one page. Preview it with sample data, then open it live with a free account.
Preview the PHVS dossierActive signals for PHVS
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 5.2%, EPS $-0.70 vs $-0.6651 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 5.6% - EPS $-0.83 vs $-0.7862 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 12.3% - EPS $-0.597 vs $-0.6806 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 13.7% - EPS $-0.72 vs $-0.6333 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 18.8% - EPS $-0.59 vs $-0.7262 estimate
FREE, NO ACCOUNT
Every signal on PHVS, as it fires
New filings, 13F moves and cross asset signals on PHVS land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, PHVS
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
PHVS against its peers
PHVS's return on equity of -64.8% ranks in the 7th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | PHVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Operating margin | n/a | -213.7% | n/a | 16 |
| Net margin | n/a | -314.9% | n/a | 17 |
| Return on equity | -64.8% | -33.5% | 7 | 21 |
| P / E | n/a | 7.9x | n/a | 5 |
| 1 year | n/a | 16.2% | n/a | 21 |
Peers (23): BCRX, VERA, AUPH, VRDN, IMNM, MLYS, NRIX, NVAX, ADMA, VCEL, CLDX, RXRX, SLS, IRON, PVLA, VIR, LKFT, NAMS, SRPT, AGIO, MESO, MBX, ZYME. Left out: ZLDPF (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PHVS: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PHVS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PHVS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.